What Happened

Biogen will acquire RayThera for up to $1 billion, gaining three preclinical anti-inflammatory therapies. The deal follows Biogen's $5.6 billion Apellis acquisition in March 2026, demonstrating accelerated M&A activity under CEO Chris Viehbacher.

Who Is Affected

RayThera's investors (Foresite Capital, OrbiMed) will receive payouts. Biogen's immunology commercial teams now have three new pipeline assets to prepare for. Competitors in SLE and nephropathy markets face strengthened competition.

Market Impact

• Expands Biogen's immunology footprint with early-stage assets
• Follows Apellis buy, showing strategic focus on kidney/immune diseases
• RayThera's Series A investors exit via acquisition

What to Watch

Closing expected Q3 2026. Monitor Phase 1 start dates for RayThera's lead program. Biogen's litifilimab Phase 3 SLE data (Q4 2026) could create parallel commercial opportunities.